Who are Gilead Sciences's decision-makers?
Gilead Sciences is led by Daniel O'Day. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Daniel O'Day
- CFO/key exec
- Andrew Dickinson
- Founded
- 1987
- Employees
- 18,000+
- HQ
- Foster City, CA
- Status
- Nasdaq: GILD
- Daniel O'DayChairman and Chief Executive OfficerCEO since 2019Leads Gilead's HIV franchise, oncology expansion, and capital allocation.
- Andrew DickinsonChief Financial OfficerCFO since 2019Oversees finance, corporate development, and investor planning.
- Dietmar BergerChief Medical OfficerCMO in 2026Guides clinical development across virology, oncology, and inflammation.
- Johanna MercierChief Commercial OfficerSenior commercial leaderRuns global commercial strategy and launch execution.
Who leads Gilead Sciences?
Gilead Sciences's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Gilead Sciences?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Gilead Sciences organized as it scales?
Gilead Sciences operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Gilead Sciences leadershipGilead Sciences annual reports
Gilead Sciences — frequently asked questions
